Lyell Immunopharma Inc - ESG Rating & Company Profile powered by AI
Comprehensive ESG assessment of Lyell Immunopharma Inc can be reached by registering for free. This webpage displays a free Environmental, Social and Governance analysis for Lyell Immunopharma Inc. The ESG score includes 17 United Nations SDGs including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Peace, Justice & Strong Institutions'.
Lyell Immunopharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.0; made up of an environmental score of 2.7, social score of 2.3 and governance score of 4.0.
3.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1309 | Willow Biosciences Inc | 3.1 | Medium |
| 1309 | biOasis Technologies Inc | 3.1 | Medium |
| 1336 | Lyell Immunopharma Inc | 3.0 | Medium |
| 1336 | BridgeBio Pharma Inc | 3.0 | Medium |
| 1336 | Absci Corp | 3.0 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Lyell Immunopharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Lyell Immunopharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Lyell Immunopharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Lyell Immunopharma Inc offer flexible work?
Sign up for free to unlockDoes Lyell Immunopharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Lyell Immunopharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Lyell Immunopharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose water use targets?
Sign up for free to unlockDoes Lyell Immunopharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Lyell Immunopharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Lyell Immunopharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Lyell Immunopharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Lyell Immunopharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Lyell Immunopharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Lyell Immunopharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose its waste policy?
Sign up for free to unlockDoes Lyell Immunopharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose energy use targets?
Sign up for free to unlockDoes Lyell Immunopharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Lyell Immunopharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Lyell Immunopharma Inc
These potential risks are based on the size, segment and geographies of the company.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.